register

News & Trends - Pharmaceuticals

First investigational gene therapy trial for macular degeneration

Health Industry Hub | May 3, 2021 |
[Total: 1    Average: 5/5]

Pharma News: Australia’s first clinical trials of an investigational gene therapy to treat dry age-related macular degeneration (AMD) has begun.

Centre for Eye Research Australia (CERA) Principal Investigator of Retinal Gene Therapy Research and vitreoretinal surgeon Dr Tom Edwards performed the first surgeries to administer this investigational gene therapy to patients at the Royal Victorian Eye and Ear Hospital in Melbourne.

This investigational gene therapy, being developed by Gyroscope Therapeutics Limited, is being studied in two studies evaluating its safety and effectiveness for the treatment of geographic atrophy (GA) secondary to AMD.

AMD causes a gradual and permanent loss of central vision that worsens over time.

“Having the dry form of AMD is a devastating diagnosis, which robs people of their ability to read, drive or even see the faces of loved ones,’’ says Dr Edwards.

You may also like Industry alliance to be the united voice for Australia’s genomics future

“There is currently no approved treatment for dry AMD. As dry AMD advances, it leads to an irreversible degeneration of retinal cells, causing a gradual and permanent loss of central vision.

“We look forward to advancing important research for people facing devastating vision loss.”

Gyroscope Therapeutics Limited recently announced it has raised USD $148.0 million (£107.8 million) in a Series C financing to advance the clinical development of GT005, the company’s lead investigational gene therapy being evaluated for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

These funds will also enable Gyroscope to further advance its early stage pipeline and innovative delivery technology, including its proprietary OrbitTM subretinal delivery system, which is designed for precise delivery to the back of the eye.

Around 20 Australians with dry AMD are expected to take part in the Phase II HORIZON and EXPLORE trials evaluating the safety and effectiveness of this investigational gene therapy.

Khurem Farooq, Chief Executive Officer, Gyroscope said “We recently announced encouraging Phase I/II clinical trial data with our lead investigational gene therapy, GT005, that give us confidence in its potential as a treatment for geographic atrophy and are continuing to advance our Phase II clinical programme.”


About the author

About the author

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nam luctus finibus scelerisque. Nunc bibendum ipsum sed augue fringilla fringilla. Nullam at consectetur leo. Praesent viverra rutrum porta. Quisque vitae mi vel purus vulputate tincidunt. Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos. Suspendisse et mi quis nisi rhoncus feugiat at ac tellus. Sed aliquam sodales nulla ac auctor. Sed pretium lobortis purus accumsan ullamcorper. Phasellus sodales vel odio in lobortis. Duis maximus sagittis bibendum. Interdum et malesuada fames ac ante ipsum primis in faucibus. Nunc dictum tincidunt ipsum in vestibulum. Donec ut sem consectetur, aliquam quam vitae, pharetra orci. Nam egestas non velit eu rhoncus. Duis congue neque non lacus tincidunt porta. Vestibulum ultricies pulvinar sem, molestie congue dui aliquet non.
  • Ut imperdiet leo id lorem fermentum consectetur.
  • Ut vitae orci et dui varius tincidunt.
  • Ut id magna non libero vestibulum pharetra ac faucibus nulla.
Aliquam erat volutpat. Vestibulum vitae varius diam. Nulla eget congue ante. Nunc ullamcorper sagittis augue vel dictum. Mauris finibus nibh ut pulvinar auctor. Vestibulum ut faucibus nisi. Orci varius natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Quisque porta tortor ac justo malesuada elementum. Nulla tellus ante, cursus nec ex sit amet, suscipit bibendum arcu. Duis posuere orci dui, et mollis enim dictum at. Sed ullamcorper, sapien ut vulputate viverra, sem purus porttitor tellus, nec mattis mauris ligula sed risus. Nulla sagittis id ipsum eu mattis. Link to full profile

Digital & Innovation

Healthcare Technology Digital Innovations - Genomics industry making headlines at HealthData21

Genomics industry making headlines at HealthData21

Health Industry Hub | May 13, 2021 |

Australia’s new genomics industry alliance Industry Genomics Network Alliance (InGeNA) will bring together representatives from the key sectors of diagnostics, […]

More


News & Trends - Medical Technology

MedTech News - B. Braun launches renal care centre in NSW and QLD

B. Braun launches renal care centres in NSW and QLD

Health Industry Hub | May 13, 2021 |

MedTech News: B. Braun, one of the world’s leading providers of medical devices, dialysis products and renal care services has […]

More


News & Trends - Pharmaceuticals

Pharma News - BMS immunotherapy combo approved in aggressive thoracic cancer

BMS immunotherapy combo approved in aggressive thoracic cancer

Health Industry Hub | May 13, 2021 |

Pharma News: Bristol-Myers Squibb (BMS) welcomed the Therapeutics Goods Administration (TGA) registration of its immunotherapy combination drugs for the first-line […]

More


News & Trends - Pharmaceuticals

Pharma News - GSK bridges the skills gap between academia and pharma industry

GSK bridges the skills gap between academia and pharma industry

Health Industry Hub | May 13, 2021 |

Pharma News: Six PhD graduates have recently traded in their lab coats for laptops after landing a place in a […]

More